Using royal jelly to reduce inflammation and oxidative stress in people with high blood pressure
Royal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension
This study is testing if royal jelly can help reduce inflammation and oxidative stress in people with high blood pressure who are already taking medication.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 34 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Universidade Federal Fluminense Academic / other |
| Locations | 1 site (Rio de Janeiro) |
| Trial ID | NCT06917131 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effects of royal jelly on inflammation and oxidative stress in individuals with systemic arterial hypertension. It is designed as a longitudinal double-blind randomized clinical trial lasting two months, involving participants who are already on antihypertensive medications. The research aims to explore the potential of royal jelly, known for its antioxidant and anti-inflammatory properties, as a natural supplement for managing hypertension. The study will compare the effects of royal jelly against a placebo to determine its efficacy in improving health outcomes.
Who should consider this trial
Good fit: Ideal candidates are patients with systemic arterial hypertension who are currently on one to three antihypertensive medications and have stable medication doses.
Not a fit: Patients with autoimmune diseases, diabetes, chronic kidney disease, liver disease, cancer, or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a natural supplement option for managing hypertension and reducing related health risks.
How similar studies have performed: While there is promising data from in vitro and animal studies regarding royal jelly, clinical studies in human populations are still limited, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients using one to three antihypertensive medications, undergoing regular follow-up at the HUAP Medical Clinic for more than 6 months and without the need for changes in medication doses in the last 3 months. Exclusion Criteria: * Patients with autoimmune and infectious diseases, diabetes, chronic kidney disease, liver disease, cancer and AIDS will be excluded; pregnant women; those using catabolic drugs or antibiotics; use of antioxidant vitamin supplements, prebiotics, probiotics, symbiotics, habitual intake of royal jelly, and who are allergic to cornstarch or report having an allergy to bee stings will also be excluded. Patients with acute myocardial infarction (AMI) and/or stroke (CVA) in the last 6 months will also be excluded; with HAS stages 2 or 3.
Where this trial is running
Rio de Janeiro
- Denise Mafra — Rio de Janeiro, Brazil (Recruiting)
Study contacts
- Principal investigator: Ludmila Cardozo, PhD — Universidade Federal Fluminense
- Study coordinator: Denise mafra, PhD
- Email: dmafra30@gmail.com
- Phone: +5521985683003
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.